ACE and COVID-19: Patients with COVID-19 are more likely to have a serious infection, or to die, if they also have comorbidities, including cardiovascular and cerebrovascular disease, conditions commonly treated with ACE inhibitors (ACEi) or angiotensin receptor blockers (ARBs) [2,3,4].